Lydia Roy

5.2k total citations · 1 hit paper
65 papers, 2.1k citations indexed

About

Lydia Roy is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Lydia Roy has authored 65 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 41 papers in Genetics and 29 papers in Rheumatology. Recurrent topics in Lydia Roy's work include Chronic Myeloid Leukemia Treatments (46 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Eosinophilic Disorders and Syndromes (28 papers). Lydia Roy is often cited by papers focused on Chronic Myeloid Leukemia Treatments (46 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Eosinophilic Disorders and Syndromes (28 papers). Lydia Roy collaborates with scholars based in France, United States and Germany. Lydia Roy's co-authors include François Guilhot, Richard A. Larson, Joëlle Guilhot, William Vainchenker, Sélim Corm, Najet Debili, Timothy P. Hughes, Andreas Hochhaus, Jane F. Apperley and Jeffrey H. Lipton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Lydia Roy

60 papers receiving 2.0k citations

Hit Papers

Adverse events associated with JAK inhibitors in 126,815 ... 2022 2026 2023 2024 2022 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    2022 99 citations Léa Hoisnard, Bénédicte Lebrun‐Vignes et al. Scientific Reports profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lydia Roy France 22 1.4k 1.1k 719 551 329 65 2.1k
Éric Lippert France 23 1.3k 0.9× 1.4k 1.3× 603 0.8× 968 1.8× 278 0.8× 102 2.2k
Rachel Okabe United States 15 1.0k 0.7× 1.0k 0.9× 332 0.5× 1.2k 2.2× 379 1.2× 22 2.0k
Christoph Walz Germany 25 792 0.6× 679 0.6× 694 1.0× 650 1.2× 375 1.1× 70 2.1k
Raajit K. Rampal United States 30 1.6k 1.1× 1.6k 1.5× 632 0.9× 1.7k 3.1× 495 1.5× 178 3.3k
Friedrich Wimazal Austria 24 1.1k 0.8× 626 0.6× 351 0.5× 344 0.6× 189 0.6× 52 2.0k
Yaping Shou United States 25 1.8k 1.3× 1.5k 1.3× 826 1.1× 1.1k 2.0× 686 2.1× 68 3.1k
Sandra Moore United States 9 1.1k 0.8× 1.3k 1.2× 445 0.6× 978 1.8× 254 0.8× 11 1.7k
Kimberly Hayes United States 19 833 0.6× 753 0.7× 263 0.4× 428 0.8× 337 1.0× 38 1.5k
Giovanna Rege‐Cambrin Italy 21 1.4k 1.0× 893 0.8× 352 0.5× 612 1.1× 293 0.9× 70 2.0k
Olivier Kosmider France 26 1.6k 1.1× 1.0k 0.9× 236 0.3× 1.2k 2.2× 220 0.7× 107 2.5k

Countries citing papers authored by Lydia Roy

Since Specialization
Citations

This map shows the geographic impact of Lydia Roy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Roy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Roy more than expected).

Fields of papers citing papers by Lydia Roy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Roy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Roy. The network helps show where Lydia Roy may publish in the future.

Co-authorship network of co-authors of Lydia Roy

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Roy. A scholar is included among the top collaborators of Lydia Roy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Roy. Lydia Roy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cullot, Grégoire, Valérie Lagarde, Jean-Michel Cayuela, et al.. (2025). Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient. Annals of Hematology. 104(2). 1117–1126.
2.
Roy, Lydia, et al.. (2024). “Give us fresh fruit.” Students’ Perceptions of the School Food Environment Compared to Skin Carotenoid Levels. Current Developments in Nutrition. 8. 102744–102744. 1 indexed citations
3.
Roy, Lydia, et al.. (2024). Fruit and Vegetable Food Waste is Correlated With Low Skin Carotenoid Levels in Middle School Students. Journal of Nutrition Education and Behavior. 56(8). S42–S42. 1 indexed citations
4.
5.
Hoisnard, Léa, Bénédicte Lebrun‐Vignes, Sébastien Maury, et al.. (2022). Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Scientific Reports. 12(1). 7140–7140. 99 indexed citations breakdown →
6.
Leclerc, Mathieu, Rabah Redjoul, Anne Le Bouter, et al.. (2022). Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients. Journal of Hematology & Oncology. 15(1). 27–27. 10 indexed citations
7.
Barbarin, Alice, Lucie Lefèvre, Émilie Cayssials, et al.. (2020). Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib. Scientific Reports. 10(1). 3245–3245. 7 indexed citations
8.
Heiblig, Maël, Delphine Réa, Marie‐Lorraine Chrétien, et al.. (2018). Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Experimental Hematology. 67. 41–48. 31 indexed citations
9.
Jacomet, Florence, Émilie Cayssials, Alice Barbarin, et al.. (2017). The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia. Frontiers in Immunology. 7. 688–688. 15 indexed citations
10.
de’Angelis, Nicola, Solafah Abdalla, Vincenzo Lizzi, et al.. (2017). Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy. Surgery. 162(6). 1219–1230. 31 indexed citations
11.
Roy, Anita, Larissa Lordier, Catherine Pioche‐Durieu, et al.. (2016). Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. Haematologica. 101(12). 1469–1478. 18 indexed citations
12.
Levescot, Anaïs, Stéphane Flamant, Florence Jacomet, et al.. (2014). BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients. Cancer Research. 74(10). 2669–2676. 41 indexed citations
13.
Martin‐Lannerée, Severine, Imen Najjar, Isabelle Plo, et al.. (2013). Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells. Cancer Research. 73(7). 2052–2058. 57 indexed citations
14.
Guilhot, François, Lydia Roy, & Cécile Tomowiak. (2012). Current treatment strategies in chronic myeloid leukemia. Current Opinion in Hematology. 19(2). 102–109. 12 indexed citations
15.
Sorel, Nathalie, Caroline Mayeur‐Rousse, Lydia Roy, et al.. (2010). Comprehensive Characterization of a Novel Intronic Pseudo-Exon Inserted within an e14/a2 BCR-ABL Rearrangement in a Patient with Chronic Myeloid Leukemia. Journal of Molecular Diagnostics. 12(4). 520–524. 9 indexed citations
16.
Guilhot, François & Lydia Roy. (2009). Dasatinib regimens for patients with chronic myeloid leukemia. Nature Reviews Clinical Oncology. 6(12). 680–682. 2 indexed citations
17.
Guilhot, François, et al.. (2007). Immunotherapy in Chronic Myelogenous Leukemia. Clinical Lymphoma & Myeloma. 7. S64–S70. 5 indexed citations
18.
19.
Royer, Bruno, Bertrand Arnulf, Frank Martinez, et al.. (2004). High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney International. 65(2). 642–648. 75 indexed citations
20.
Ferguson, Kevin L., François Guilhot, Laurence Lacotte, et al.. (2002). Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 16(2). 186–195. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Lippert Breakdown of academic impact, for papers by Rachel Okabe Breakdown of academic impact, for papers by Christoph Walz Breakdown of academic impact, for papers by Raajit K. Rampal Breakdown of academic impact, for papers by Friedrich Wimazal Breakdown of academic impact, for papers by Yaping Shou Breakdown of academic impact, for papers by Sandra Moore Breakdown of academic impact, for papers by Kimberly Hayes Breakdown of academic impact, for papers by Giovanna Rege‐Cambrin Breakdown of academic impact, for papers by Olivier Kosmider
Rankless by CCL
2026